Clinical Trial Update: Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describing CD19-targeted CAR T-cell immunotherapy for high-risk or relapsed CD19+ acute lymphoblastic leukemia, B-cell non-Hodgk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CD19-targeted CAR T-cell therapy (clinical trial) (CD19 CAR T-cell therapy)

Snippet

Sponsor: University College, London | Conditions: Leukemia, Lymphoblastic, Acute, Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING